A TDF based measure of the behavioural determinants of MTB was developed.
Introduction
Clinical guidelines recommend that women with hormone receptor positive breast cancer receive at least five, and up to 10, years of adjuvant hormonal therapy as a preventative measure for breast cancer recurrence and mortality. (Davies et al., 2011) However, despite the proven clinical efficacy of adjuvant hormonal therapy many women do not take their treatment as recommended. Reduced hormonal therapy exposure due to early treatment discontinuation (non-persistence) or failure to take the correct dosage at the prescribed frequency (non-adherence) is associated with an increased risk of early breast cancer recurrence and mortality. (Barron, Cahir, Sharp, & Bennett, 2013; Chirgwin et al., 2016; Hershman et al., 2011) Rates of non-persistence at 5 years range from 16% to 32% in clinical trials of hormonal treatment and between 31% and 73% in routine clinical settings, while prevalence of non-adherence ranges from 41% to 72%. (Barron, Connolly, Bennett, Feely, & Kennedy, 2007; Murphy, Bartholomew, Carpentier, Bluethmann, & Vernon, 2012) Despite the high prevalence of hormonal therapy non-persistence and non-adherence little is known about the risk factors associated with hormonal therapy medication taking behaviour (MTB). Recent systematic reviews have identified follow-up care with a general practitioner (compared to follow-up by an oncologist) and experience of treatment side-effects as largely negatively associated with persistence, while taking more medications at baseline has been positively associated with persistence. (Cahir, Guinan, Dombrowski, Sharp & Bennett, 2015; Murphy et al., 2012 ) These reviews highlighted a critical need to identify potentially modifiable determinants that influence hormonal therapy MTB in order to develop behavioural interventions to improve this behaviour.
The Theoretical Domains Framework (TDF) is an integrative framework of multiple theories of behaviour change designed to assess complex behavioural issues such as MTB and inform intervention design. (Cane, O'Connor, & Michie, 2012; Michie et al., 2005; Michie, Johnston, Francis, Hardeman, & Eccles, 2008) The TDF has recently been validated and refined to include 14 domains of potential behavioural determinants. (Cane et al., 2012) . A number of studies have applied the TDF to assess potential behavioural determinants across a range of clinical settings and populations. (Cahir et al., 2014; Penn, Dombrowski, Sniehotta &White, 2013; Dombrowski, et al., 2012; McSherry et al., 2012) However, the majority of these studies have used qualitative interviews which limit the generalisability of the findings. (Francis, O'Connor & Curran, 2012) A small number of TDF based questionnaires have been developed, which have assessed the behavioural determinants of, for example, smoking cessation in dental healthcare (Amemori, Michie, Korhonen, Murtomaa, & Kinnunen, 2011) and maternal care (Beenstock et al., 2012) , patient safety behaviours in hospital (Taylor, Parveen, Robins, Slater, & Lawton, 2013) and healthcare professionals implementation behaviour. (Huijg et al., 2014) The TDF has not been used to develop a questionnaire measuring the behavioural determinants of MTB.
The aim of the current study is to develop a questionnaire measuring the behavioural determinants of hormonal therapy MTB based on the 14 domain version of the TDF (Cane et al., 2012) and to test the psychometric properties of this questionnaire in a sample of women with stage I-III breast cancer prescribed hormonal therapy.
Methods

Development of the TDF questionnaire measuring the modifiable determinants of hormonal therapy MTB
The TDF questionnaire items were developed from previous research by the research team including; (i) a systematic review of the modifiable influences on adjuvant hormonal therapy MTB (Cahir et al., 2015) ; (ii) in depth interviews with women with stage I-III breast cancer prescribed adjuvant hormonal therapy (Cahir et al., 2014) Influences. Each domain is defined as a group of related theoretical constructs (where constructs are defined as component part of theories, such as 'attitude', 'self-efficacy', 'anxiety'). For example, the domain Social Influences includes the constructs social support, group norms, social comparisons and several others and the constructs are grouped together to represent the influences of people on others' behaviours. (Francis et al., 2012; Michie et al., 2005) In meta-analysis three domains (Beliefs about Capabilities, Social Influences, and Behaviour Regulation) were found to be associated with hormonal therapy MTB. However several domains associated with MTB in other disease groups including Beliefs about Consequences, Intentions, Goals, Social Identity, Emotion and Knowledge which have been reported to influence MTB in other disease groups were not examined. (Cahir et al., 2015) In-depth interviews were conducted with thirty-one women (14 adherent and persistent, 7 non-adherent and persistent, 10 non-persistent) with stage I-III breast cancer prescribed adjuvant hormonal therapy at two cancer centres in Ireland with the TDF informing the analysis framework. Key enablers for adherent and persistent women, based upon prespecified criteria, were identified within the domain Beliefs about Consequences (breast cancer recurrence), Intentions and Goals (high-priority), Beliefs about Capabilities (side-effects) and Behaviour Regulation (managing medication). Adherent and persistent women strongly believed in the efficacy and necessity of their therapy, were highly motivated and adapted a wide range of coping techniques and support networks to enable them to take their treatment and manage side-effects. Key barriers, based upon pre-specified criteria, were identified within the domain Behaviour Regulation (no routine), Memory, Attention and Decision Processes (forgetting) and Environmental Context and Resources (stressors) for non-adherent and persistent women and Intentions and Goals (quality of life), Behaviour Regulation (temporal self-regulation), Reinforcement, Beliefs about Consequences (nonnecessity) and Social Influences (clinical support) for non-persistent women. Non-adherence was associated with inadequate medication management techniques and non-persistence was associated with a strong distrust of medication and the health care system, a lack of perceived need for treatment and a preference for a good quality of life with little concern or thought given to future outcomes. (Cahir et al., 2014) The findings from both the systematic review and qualitative interviews were combined and 9 domains and their related constructs were identified as key domains for the MTB questionnaire. (Cahir et al., 2014; Cahir et al., 2015) (Appendix I) The refined framework for the MTB questionnaire, based on previous research, did not include the domain Skills as the only skill proficiency required was to swallow a tablet daily. The domains Intentions and Goals and Reinforcement were included as one domain (Intentions and Goals and Reinforcement) in line with the original 12 domain TDF (Intentions and Goals) and Reinforcement was included based on the qualitative interviews where goal conflict and goal facilitation and reinforcement were shown to be contingent on each other. (Cahir et al., 2014; Michie et al., 2005) Within the qualitative interviews we found that women who were nonpersistent with their hormonal therapy wanted to be finished with their treatment (Intentions and Goals) and felt their treatment conflicted with their everyday life and plans (goal conflict). Many women reported an improvement in their quality of life and feeling "back to myself" once they ceased their treatment (Reinforcement). (Cahir et al., 2014) The domain Optimism was renamed Personality and extended to include other personality constructs, such as resilience which had emerged from the qualitative interviews. (Cahir et al., 2014) The domain Personality was included with the domain Beliefs about Capabilities as only one key construct "resilience" was relevant to MTB within the domain Personality and "resilience" was associated with "coping skills" within the domain Beliefs about Capabilities. This is in line with the original 12 domain TDF where the domain Optimism was included in the domain Beliefs about Capabilities. (Michie et al., 2005) Similarly, the domain Emotion was included with the domain Beliefs about Consequences as only one key construct "worry about breast cancer recurrence" was relevant to MTB within the domain Emotion and this was associated with outcome expectancies in the domain Beliefs about Consequences.
Potential individual validated scales for each construct within each domain were identified from the systematic review on potentially modifiable determinants of hormonal therapy MTB and the broader literature on MTB across other disease groups e.g. action planning, coping planning within the domain Behaviour Regulation. (Cahir et al., 2015) The identified individual scales for each construct were reviewed by a health psychologist (SD) and discussed with the broader research team (CC, LS, KB) and a consensus was reached on the measures for each construct. The consensus on the individual scales was informed by the academic literature on the scales, the definition of the constructs and domains as formulated by Michie et al. (Michie et al., 2005) and the specific constructs and domains that emerged from the interviews with women with stage I-III breast cancer prescribed hormonal therapy. 
Statistical analysis
Confirmatory factor analysis (CFA) was used to examine whether the items measuring the behavioural determinants of hormonal therapy MTB were a good fit to the TDF. CFA was considered appropriate to test the theoretical framework (TDF) and to establish the initial construct validity of the questionnaire and remove unnecessary or deficient items. Sample size guidance indicated that 200 to 300 participants would be adequate for CFA analysis. (Bryant & Yarnold, 1995) . The data was screened and descriptive statistics were examined for all items, prior to data analysis including measures of central tendency, variability and dispersion (skew, kurtosis) using Stata Version 14 (Stata Corporation, College Station, TX, USA).
CFA was used to test the 9 factor model using weighted least square estimates (WLSMV). 
Results
Descriptive statistics
In total 223 women with stage I-III breast cancer and prescribed hormonal therapy completed the questionnaire on MTB (response rate= 61% , N=367 eligible participants). The average age was 61 years (SD=13.9) and 118 women (54.6%) were married. Sixty-five women (29.7%) had third level education and 60 women (28.4%) were currently employed outside of the home. Missing value analysis indicated that the data was missing at random (< 7% missing data across individual measures) and data was imputed using weighted least squares estimation. (Asparouhov & Muthén, 2010) One hundred and ninety-three women (88.5%) reported being both adherent and persistent with their hormonal therapy since commencing treatment; 12 women (5.5%) reported missing doses on a regular basis (non-adherent and persistent) and 13 women (6.0%) reported that they had stopped taking their hormonal therapy (non-persistent). No women reported never initiating their treatment. Non-adherent and persistent women and non-persistent women had significantly higher self-reported non-adherence scores (Voils scale) compared to adherent and persistent women (F(2,196) = 4.72, p = 0.01). (Table 1) .
Confirmatory factor analysis
The initial CFA including the 9 domains showed that the data did not fit the model Table 2 .
Internal consistency
The average inter item correlations (r) for each domain ranged from 0. Environment demonstrating adequate levels (r > 0.15 and r < 0.50) of internal consistency (Table 2) .
Discriminant validity
Six domains were found to display discriminant validity according to Fornell and Larkner (1981) combination of domains in a generic questionnaire of behavioural determinants and that these domains may not be able to be discriminately measured. They also found that items measuring general feelings (e.g. stress) were able to discriminately assess the domain Emotion while emotions relating to performing a specific behaviour (e.g. affect) were not able to. In the current study emotions relating to the behaviour of taking/not taking hormonal therapy were determined to be measured by the domain Beliefs about Consequences.
There are a number of limitations to this study which need to be taken into consideration when interpreting the results. Hence, although the application of the TDF enables a comprehensive measure of the behavioural determinants of MTB, the number of domains and underlying constructs need to be assessed by a large amount of items and existing scales were not available for some unique aspects of MTB. The selection of constructs within each domain was based on previous research and expert guidance but these constructs may not in fact be highly relevant to hormonal therapy MTB or may not have been effectively measured leading to decreased validity of the measurement of some domains. Equally some constructs which were excluded based on previous research may in fact be relevant. Further work is required to establish which constructs are essential for determining MTB and adequately measure the given domains.
One of limitations of the TDF in its current form is that it is a descriptive framework and it does not specify relationships between domains. (Francis et al., 2012) This study has also not established the criterion validity of the questionnaire on hormonal therapy MTB. Women in the sample were asked to self-report their hormonal therapy MTB and there was some indication of differences across domains for the different MTB groups but the numbers within each group were too small for formal analysis. A larger scale study of women with stage I-III breast cancer prescribed hormonal therapy is currently underway to establish criterion validity and this will also identify the key domains and determinants of hormonal therapy MTB and assess potential relationships between them. This will enable the development of a more refined and effective questionnaire that can be used in clinical practice. Prospective cohort studies are also needed to investigate the predictive validity of the questionnaire and the extent each domain can predict future hormonal therapy MTB.
Notwithstanding the further work required to improve the reliability, validity and generalisability of the questionnaire, a theoretical based measure of the behavioural determinants of hormonal therapy MTB has been developed and can be used as a tool for considered to be large. (Brown, 2015) DiMatteo, M. R., Hays, R. D., Gritz, E. R., Bastani, R., Crane, L., Elashoff, R., . . . Marcus, A. (1993 * Missing data for 5 women ** Non-persistent women were no longer taking hormonal therapy and reported adherence was in relation to when they were taking hormonal therapy (prior to stopping) 171 (82) Relationship with oncologistunderstanding (yes)
166 (80) Relationship with oncologistrespect (yes)
177 (85) Relationship with oncologist-time (yes) 155 (75)
Median (IQR) Beliefs about Capability
Action self-efficacy 10 (9 ,10) 0.35 Maintenance self-efficacy 10 (9, 10) Recovery self-efficacy 10 (9, 10) Resilience 4 (3 ,4)
Median (IQR) Beliefs about Consequences
Perceived severity of breast cancer 9 (8 ,11) 0.16
Perceived susceptibility to breast cancer 11 (9, 12) Perceived utility of adhering to hormonal therapy 15 (11, 18) Illness perceptions 9 (7, 10) Beliefs about hormonal therapy-necessity 16 (14, 18) Beliefs about hormonal therapy-concerns 12 (10, 15) Outcome expectancies-perceived outcomes if take/don't take hormonal therapy 11 (9, 13) Outcome expectancies-perceived cancer recurrence risk if take hormonal therapy -0.88 (-1.59, 0.04)
Outcome expectancies-perceived cancer recurrence risk if don't take hormonal therapy 0.04 (-0.54, 0.75) Concern about breast cancer recurrence 2 (1 , 2)
Median (IQR) Intentions, Goals and
Intention to take hormonal therapy as 14 (14, 14) 0.64
